Abstract
This paper critically examines the implications of state efforts to expand prescriptive authority of pharmacists, which will allow them to prescribe various types of hormonal contraceptives. With this expansion, women no longer need to see a physician before being prescribed such contraceptives, but instead, they must answer self-assessment questionnaires at the pharmacy to ensure that their chosen method is safe and appropriate. This paper argues that while these measures to expand pharmacists’ prescriptive authority will surely meet the stated goal to increase access to hormonal contraceptives, the measures may have detrimental consequences that have largely been downplayed. Studies consistently show that the OB-GYN is a significant primary care provider identified by young female patients, and some of the main reasons provided by these young women for going to the OB-GYN is to discuss, or obtain a prescription for, contraceptives. Through the expansion of pharmacists’ prescriptive authority, a likely consequence is that some women will relinquish going to the OB-GYN. However, the OB-GYN provides important services beyond contraceptives, such as preventive screenings for hypertension, cardiovascular diseases, alcohol abuse, mental health, etc., and there is evidence supporting both the effectiveness and cost–benefits of these interventions. By increasing access to contraceptives, the likely result is that many women will have less interaction with a physician and will receive fewer preventive screenings. I do not wish to suggest that these bills should not pass, nor that OB-GYNs should hold contraceptives hostage, only that there are consequences to expanded prescriptive authority that must be anticipated. Further, expanding prescriptive authority obscures the real problem: some individuals have trouble accessing the health care system, not merely trouble accessing hormonal contraceptives. The expansion of prescriptive authority to include contraceptives applies a Band-Aid to treat one aspect of this problem. What is needed is not merely expanded access to hormonal contraceptives, but better access to health care in general.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Notes
Excluding miscarriages.
Which type of contraceptive, whether oral, patch, ring, or injection, is state dependent.
References
American College of Obstetricians and Gynecologists (ACOG). (2012). ACOG statement on HR 3803. Washington, DC.
American College of Obstetricians and Gynecologists (ACOG). (2016). Well-woman recommendations. Washington, DC.
Becker, H. I., Longacre, M. R., & Harper, D. M. (2004). Beyond the pap: Assessing patients’ priorities for the annual examination. Journal of Women’s Health,13(7), 791–798.
Biggs, M. A., Karasek, D., & Foster, D. G. (2012). Unprotected intercourse among women wanting to avoid pregnancy: Attitudes, behaviors, and beliefs. Women’s Health Issues,22(3), e311–318.
Center for Disease Control and Prevention (CDC). (2016). Chronic diseases: The leading causes of death and disability in the United States. http://www.cdc.gov/chronicdisease/overview/index.htm. Accessed 27 July 2019.
Ettner, S. L. (1999). The relationship between continuity of care and the health behaviors of patients: Does having a usual physician make a difference? Medical Care,39(6), 547–555.
Farr, S. L., Hayes, D. K., Bitsko, R. H., Bansil, P., & Dietz, P. M. (2011). Depression, diabetes, and chronic disease risk factors among US women of reproductive age. Preventing Chronic Disease,8(6), A119.
Finer, L. B., & Zolna, M. R. (2011). Unintended pregnancy in the United States: Incidence and disparities, 2006. Contraception,84(5), 478–485.
Finer, L. B., & Zolna, M. R. (2016). Declines in unintended pregnancy in the United States, 2008–2011. New England Journal of Medicine,374(9), 843–852.
Food and Drug Administration (FDA). (2011). Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints. Silver Spring, MD. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf. Accessed 27 July 2019.
Food and Drug Administration (FDA). (2012). FDA drug safety communication: Updated information about the risk of blood clots in women taking birth control pills containing drospirenone. Silver Spring, MD. http://www.fda.gov/Drugs/DrugSafety/ucm299305. Accessed 27 July 2019.
Foster, D. G., Higgins, J. A., Karasek, D., Ma, S., & Grossman, D. (2012). Attitudes toward unprotected intercourse and risk of pregnancy among women seeking abortion. Women’s Health Issues,22(2), e149–155.
Gorenoi, V., Schönermark, M. P., Hagen, A. (2007). Benefits and risks of hormonal contraception for women. GMS Health Technology Assessment,3, Doc6.
Greene, M. E., & Merrick, T. (2015). The case for investing in research to increase access to and use of contraception among adolescents. Alliance for Reproductive, Maternal, and Newborn Health. Seattle, WA.
Grindlay, K., Burns, B., & Grossman, D. (2013). Prescription requirements and over-the-counter access to oral contraceptives: A global review. Contraception,88(1), 91–96.
Grindlay, K., & Grossmann, D. (2016). Prescription birth control access among U.S. women at risk of unintended pregnancy. Journal of Women’s Health,25(3), 249–254.
Grossman, D., Fernandez, L., Hopkins, K., Amastae, J., Garcia, S. G., & Potter, J. E. (2008). Accuracy of self-screening for contraindications to combined oral contraceptive use. Obstetrics and Gynecology,112(3), 572–578.
Grossman, D., Grindlay, K., Li, R., Potter, J. E., Trussell, J., & Blanchard, K. (2013). Interest in over-the-counter access to oral contraceptives among women in the United States. Contraception,88(4), 544–552.
Hayes, D. K., Fan, A. Z., Smith, R. A., & Bombard, J. M. (2011). Trends in selected chronic conditions and behavioral risk factors among women of reproductive age, Behavioral risk factor surveillance system, 2001–2009. Preventing Chronic Disease,8(6), A120.
Henderson, J. T., Sawaya, G. F., Blum, M., Stratton, L., & Harper, C. C. (2010). Pelvic examinations and access to oral hormonal contraceptives. Obstetrics and Gynecology,116(6), 1257–1264.
Henderson, J. T., Weisman, C. S., & Grason, H. (2002). Are two doctors better than one? Women’s physician use and appropriate care. Women’s Health Issues,12(3), 138–149.
Hopkins, K., Grossman, D., White, K., Amastae, J., & Potter, J. E. (2012). Reproductive health preventive screening among clinic vs. over-the-counter oral contraceptive users. Contraception,86(4), 376–382.
Institute of Medicine (IOM). (2011). Clinical preventive services for women: Closing the gaps. Washington, DC: National Academic Press.
Jones, R. K., Darroch, J. E., & Henshaw, S. K. (2002). Contraceptive use among US women having abortions in 2000-2001. Perspectives on Sexual and Reproductive Health,34(6), 294–303.
Kaiser Family Foundation (KFF). (2005). Women and heathcare: A national profile. Washington, DC.
Kaiser Family Foundation (KFF). (2011). Women’s health care chartbook: Key findings from the Kaiser women’s health survey. Washington, DC.
Kaiser Family Foundation (KFF). (2014). Women and health in the early years of the Affordable Care Act. Washington, DC.
Kerse, N., Buetow, S., Mainous, A. G., Young, G., Coster, G., & Arroll, B. (2004). Physician–patient relationship and medication compliance: A primary care investigation. Annals of Family Medicine,2(5), 455–461.
Ko, J. Y., Farr, S. L., Dietz, P. M., & Robbins, C. L. (2012). Depression and treatment among US pregnant and non-pregnant women of reproductive age, 2005-2009. Journal of Women’s Health,21(8), 830–836.
Leopold, N., Cooper, J., & Clancy, C. (1996). Sustained partnership in primary care. Journal of Family Practice,42(2), 129–137.
Masiosek, M. V., Coffield, A. B., Flottemesch, T. J., Edwards, N. M., & Solberg, L. I. (2010). Greater use of preventive services in US health care could save lives at little or no cost. Health Affairs,29(9), 1656–1660.
McGinnis, J. M., & Foege, W. H. (1993). Actual causes of death in the United States. JAMA,270(18), 2207–2212.
McGlynn, E. A., Asch, S. M., Adams, J., Keesey, J., Hicks, J., DeCristofaro, A., et al. (2003). The quality of health care delivered to adults in the United States. New England Journal of Medicine,348(26), 2635–2645.
Peltzman, S. (1987). By prescription only. AEI Journal of Government and Society,3(4), 23–28.
Schneider, J., Kaplan, S. H., Greenfield, S., Li, W., & Wilson, I. B. (2004). Better physician-patient relationships are associated with higher reported adherence to antiretroviral therapy in patient with HIV infection. Journal of General Internal Medicine,19(11), 1096–1103.
Scholle, S. H., & Kelleher, K. (2003). Assessing primary care performance in an obstetrics/gynecology clinic. Women and Health,37(1), 15–30.
Shotorbani, S., Miller, L., Blough, D. K., & Gardner, J. (2006). Agreement between women’s and provider’s assessment or hormonal contraceptive risk factors. Contraception,73(5), 501–506.
Simon, A. E., & Uddin, S. F. G. (2017). Trends in seeing an obstetrician-gynecologist compared with a general physician among U.S. women, 2000–2015. Obstetrics & Gynecology,130(4), 677–683.
Stewart, M. A. (1995). Effective physician-patient communication and health outcomes. Canadian Medical Association Journal,152(9), 1423–1433.
U.S. Preventive Services Task Force. (2014). The guide to clinical preventive services 2014. Rockville, MD.
U.S. Preventive Services Task Force. (2018). Screening for cervical cancer: US preventive services task force recommendation statement. JAMA,320(7), 674–686.
United States Code. Title 21 - FOOD AND DRUGS; Sec. 353 - Exemptions and consideration for certain drugs, devices, and biological products (2006 ed., Supplement 5). https://www.govinfo.gov/app/details/USCODE-2011-title21/USCODE-2011-title21-chap9-subchapV-partA-sec353/summary. Accessed 29 July 2019.
World Health Organization (WHO). (2015). Medical eligibility criteria for contraceptive use (5th ed.). Geneva, Switzerland:
Acknowledgements
I wish to express my sincerest appreciation to my colleague at Creighton University, Kelly Dineen, who has offered generous feedback on an earlier version of this article.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Bendtsen, K. Bills as Band-Aids: Hopes and Challenges of Expanding Pharmacists’ Prescriptive Authority to Include Contraceptives. HEC Forum 31, 295–304 (2019). https://doi.org/10.1007/s10730-019-09380-w
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10730-019-09380-w